New-generation ektacytometry study of red blood cells in different hemoglobinopathies and thalassemia
Against that backdrop, contemporary reviews specifically examining GLP-1 agents and body composition appropriately emphasize heterogeneity across trials, measurement approaches (DEXA vs BIA), and baseline phenotypes [6,28]
Both in clinical studies and real-world studies, combined use is associated with better glycemic control
Lexarias DehydraTECH eliminated or reduced these as early as their 2024 trials, sharing that Lexarias DehydraTECH-processed Rybelsus capsules demonstrated superior tolerability in delivering the GLP-1 drug semaglutide compared to commercially available ones
Researchers optimizing their protocols should track: Body composition: Use DEXA scans, bioimpedance devices, or at minimum waist/hip measurements to distinguish fat loss from lean mass loss Resting heart rate: Particularly important with retatrutide due to the glucagon-mediated heart rate increase Blood pressure: Both peptides lower blood pressure, which is beneficial but can cause dizziness if the drop is too rapid Fasting blood glucose: Especially relevant for those managing pre-diabetes or type 2 diabetes Liver enzymes: For anyone with suspected or confirmed fatty liver disease Energy levels and sleep quality: Subjective but important indicators of protocol tolerance The GLP-1 progress tracking tools available through SeekPeptides help members monitor these metrics systematically rather than relying on memory or sporadic tracking
